Abstract
Objectives: Lipid‐based nutrient supplements (LNSs) are increasingly used inHIVprogrammes in resource‐limited settings. However, the possible effects ofLNSson the plasma concentrations of antiretroviral drugs have not been assessed. Here, we aimed to assess the effects ofLNSson plasma efavirenz and nevirapine trough concentrations inEthiopian adultHIV‐infected patients.Methods: The effects ofLNSswere studied in adults initiating antiretroviral therapy (ART) in a randomized trial. Patients with body mass index (BMI) > 17 kg/m2(n = 282) received daily supplementation of anLNScontaining whey (LNS/w), anLNScontaining soy (LNS/s) or noLNS. Trough plasma concentrations of efavirenz and nevirapine were measured at 1 and 2 months. Genotyping for 516G>Tand 983T>Cpolymorphisms of thecytochromeP450(CYP)2B6locus was performed. Multilevel linear mixed‐effects models were used to assess the associations betweenLNSand plasma efavirenz and nevirapine concentrations.Results: In patients withBMI> 17 kg/m2, nevirapine concentrations were lower in theLNS/w andLNS/s groups by a median of −2.3 μg/mL [interquartile range (IQR) −3.9; −0.9 μg/mL;P = 0.002] and −2.1 μg/mL (IQR−3.9; −0.9 μg/mL;P = 0.01), respectively, compared with the group not receiving supplements. There were no differences between groups with respect to efavirenz plasma concentrations. TheCYP2B6516G>Tpolymorphism was associated with a 5 μg/mL higher plasma efavirenz concentration compared with the wild type (P < 0.0001), while it was not associated with plasma nevirapine concentrations.Conclusions: Intake of anLNSwas associated with lower plasma nevirapine trough concentrations, indicating possible drug−LNSinteractions. The clinical relevance of such reductions in nevirapine exposure is not clear. Plasma efavirenz concentration was not affected by theLNS.
Funding Information
  • DANIDA-GRANT (09-026RH)

This publication has 29 references indexed in Scilit: